Biotech M&A on Track for Best Year Since Pre-Covid Era

Biotech mergers and acquisitions are experiencing a strong start in 2026, poised for their best year since before the Covid-19 pandemic, driven by looming patent cliffs, buoyant public markets, and Big Pharma's pipeline expansion efforts.

4 Jun, 05:45 — 4 Jun, 05:45

Post Share

Sources

Showing 1 of 1 sources

cnbcMostly Factual83d ago

‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.

Read full article →

PERSPECTA

PERSPECTA

Biotech M&A on Track for Best Year Since Pre-Covid Era

Sources

‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid

Related Stories

Italy Extends Diesel Fuel Tax Cut Through Early September

Cisco Abandons Traditional Hardware Restrictions to Pursue AI Infrastructure Boom

Executives at Itron and Lyft Sell Significant Company Stock Holdings

Senior Official Firmly Rejects External Political Pressure and Influence Attempts

PERSPECTA